Fig. 6: 43 preserves β-cell identity in glucolipotoxicity and prevents upregulation of ChREBPβ in high glucose and glucolipotoxicity.

a,b,f,g. mRNA fold-enrichment over control low glucose in human islets, treated with 10 μM 43 for 24 h; Low-5.5 mM glucose, High-20 mM glucose, glucotox-20 mM glucose+500 μM palmitate. c, d, h. Immunostaining for Pdx1, c-term ChREBP, and insulin in dispersed islets treated for 48 h with the indicated treatments. e. INS-1 cells expressing luciferase driven by the human TXNIP promoter were incubated for 24 h at the indicated glucose concentrations, in the presence or absence of 10 μM 43. Data are the means +/− SEM, n=3–7, *p<0.05, **p<0.01***, p<0.005, ****, p<0.001.